<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01035580</url>
  </required_header>
  <id_info>
    <org_study_id>IRB00020139</org_study_id>
    <nct_id>NCT01035580</nct_id>
  </id_info>
  <brief_title>Trial on Safety and Pharmacokinetics of Intravaginal Curcumin</brief_title>
  <official_title>Phase I Trial on Safety and Pharmacokinetics of Intravaginal Curcumin in Normal Female Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Emory University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Emory University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of this study is to determine the maximum tolerable dose and safety of
      intravaginal curcumin in a normal population of women (women with no evidence of cervical
      cytological abnormalities by pap testing).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">January 2012</completion_date>
  <primary_completion_date type="Actual">April 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary endpoint is to reach the maximum selected dose (MSD) or maximum tolerated dose (MTD) of intravaginal curcumin among Pap test negative women without causing a dose-limiting toxicity.</measure>
    <time_frame>14 days</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">13</enrollment>
  <condition>Uterine Cervical Dysplasia</condition>
  <arm_group>
    <arm_group_label>curcurim</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This was a 3 + 3 dose escalation trial starting at 500 mg of cur cumin capsules administered daily intravaginally for 14 days. The dose increased after safety was demonstrated in 3 subjects by 500 mg up to a max of 2000 mgs.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Curcumin</intervention_name>
    <description>Curcumin 500 mg capsules will be inserted intravaginally once daily for 14 days for a maximum daily dosage of 2000 mg</description>
    <arm_group_label>curcurim</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>curcumin</intervention_name>
    <description>all patients received the drug</description>
    <arm_group_label>curcurim</arm_group_label>
    <other_name>Sabinsa Curcumin Capsules</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Between the ages of 18-45 years of age at enrollment

          -  Currently using a reliable birth control method (oral contraceptive pills, DepoProvera
             or permanent sterilization)

          -  Able to provide written informed consent

          -  Provide male partner notification letter

          -  Have a Pap test negative pap (no cervical intraepithelial lesions) within 45 days
             prior to screening

          -  Have regular monthly menses (every 21-35 days) or amenorrhea due to hormonal
             contraceptive use

          -  Agree to undergo pelvic exam and colposcopy per protocol

          -  Able and willing to complete Study Diary

          -  Agree to wear condoms during all acts of vaginal intercourse or abstain from vaginal
             intercourse during the 14 days

          -  Agree to abstain from sexual intercourse for 48 hours prior to the enrollment visit

          -  Agree to insert curcumin gelatin capsules as required per protocol

          -  Agree to abstain from nonsteroidal anti-inflammatory drugs (NSAIDS) during the 14 days

          -  Agree to abstain from all products containing curcumin or food consumption of curcumin
             during the 14 days

          -  Agree to abstain from the following activities for at least 48 hours prior to
             enrollment through the Day 14 visit:insertion of objects into the vagina except for a
             penis, receiving oral or anal sex,using a diaphragm, cervical cap, female condom, or
             vaginal contraceptive ring,using vaginal products other than the study gelatin
             capsules, including douches, lubricants, spermicide or feminine hygiene
             products,participating in other vaginal cream or contraceptive studies

          -  Agree to testing for HIV status via enzyme immunoassay (EIA)/Western Blot

        Exclusion Criteria:

          -  Are post-menopausal

          -  Have had a hysterectomy with removal of the cervix

          -  Have a clinically significant chronic medical condition that is considered
             progressive, including: coronary disease, congestive heart failure, chronic
             obstructive lung disease, diabetes mellitus, chronic renal disease, active peptic
             ulcer disease, chronic hepatic disease, multiple sclerosis, seizure disorder requiring
             medication, and a coagulation or platelet disorder. Chronic nonprogressive or
             intermittent syndromes are not excluded, including migraine headaches, mild reactive
             airways disease, controlled hypertension, stable pain syndromes, or benign gastric
             reflux.

          -  Have an intrauterine device (IUD) as a form of birth control

          -  Have any history of malignancy or current (within 45 days of screening) pap with
             cervical intraepithelial lesions.

          -  Currently has documented lacerations on visual inspection present on the cervix,
             vagina, vulva or perineum.

          -  Are pregnant or planning to become pregnant in the next three months

          -  Are currently breastfeeding

          -  Have a history of sensitivity or allergy to any compound used in this study

          -  Have Grade 2 or higher renal or hematologic abnormality, as defined by the Table for
             Grading the Severity of Adult Adverse Events or at screening have a positive bacterial
             urine culture. Women with a positive bacterial urine culture at screening will be
             allowed to enroll after appropriate treatment if repeat evaluation is normal.

          -  In the three months prior to enrollment have had any of the following:Treatment for
             Cervical disease or any other gynecologic surgery,A pregnancy or an abortion, An
             IUD,Breakthrough menstrual bleeding or vaginal bleeding during or following vaginal
             intercourse

          -  Signs, as seen on pelvic exam at screening, consistent with an STD including
             vaginitis, cervicitis or genital ulcers

          -  Signs, as seen on pelvic exam, of genital trauma

          -  Signs of genital tract infection from laboratory evaluations. Women with Candida
             vaginitis or bacterial vaginosis at screening will be allowed to enroll after
             appropriate treatment and if repeat evaluation is normal.

          -  In the three months prior to enrollment have had any of the following:History of
             treatment for or a diagnosis with a new STD,Genital herpes simplex virus infection or
             outbreak,Exchanged sex for money, drugs or gifts

          -  Are currently using, or in the last year have used intravenous drugs (except for
             therapeutic use), cocaine or other recreational drugs, abused alcohol defined as
             alcohol use that has required hospital admission for detoxification and therapy.

          -  Have any other condition that in the opinion of the investigator might interfere with
             the evaluation of the study objectives.

          -  HIV positive
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lisa Flowers, Medical</last_name>
    <role>Principal Investigator</role>
    <affiliation>Emory University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Emory University</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30303</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 17, 2009</study_first_submitted>
  <study_first_submitted_qc>December 17, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 18, 2009</study_first_posted>
  <last_update_submitted>November 27, 2013</last_update_submitted>
  <last_update_submitted_qc>November 27, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">November 28, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Emory University</investigator_affiliation>
    <investigator_full_name>Lisa Flowers</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>chemoprevention</keyword>
  <keyword>curcumin</keyword>
  <keyword>pharmacokinetics</keyword>
  <keyword>safety</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Cervical Dysplasia</mesh_term>
    <mesh_term>Cervical Intraepithelial Neoplasia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Curcumin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

